Cabergoline 1a Farma

Information för alternativet: Cabergoline 1a Farma 1 Mg Tablett, Cabergoline 1a Farma 2 Mg Tablett, visar 2 alternativ

Package leaflet: Information for the patient

Cabergoline1A Farma 1 mg tablets

Cabergoline1A Farma 2 mg tablets


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.

- If you have any further questions, ask your doctor or pharmacist.

- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What Cabergoline1A Farmais and what it is used for

2. What you need to know before you take Cabergoline1A Farma

3. How to take Cabergoline1A Farma

4. Possible side effects

5. How to store Cabergoline1A Farma

6. Contents of the pack and other information

1. What Cabergoline1A Farma is and what it is used for

Cabergoline1A Farma belongs to a group of medicines known as dopamine agonists. It acts in a similar way to a chemical present in the nervous system called dopamine. Patients with Parkinson’s disease do not have enough of this important chemical in their body.

Cabergoline1A Farma is used to treat Parkinson’s disease. It can be used either taken alone or in combination with levodopa, as second choice following non-ergot derived therapies.

Treatment by a specialist is required with regular checks.

2. What you need to know before you take Cabergoline1A Farma

Do NOT take Cabergoline1A Farma if you:

Before you are given Cabergoline1A Farma your doctor will arrange for you to have tests to assess the condition of your heart. Your doctor will continue to monitor your medical condition while taking Cabergoline1A Farma].

Warnings and precautions

Talk to your doctor before taking Cabergoline1A Farma

If you have any of the following health problems you must inform your doctor before taking Cabergoline1A Farmaas this medicine may be unsuitable for you:

Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or an increase in sexual thoughts or feelings. Your doctor may need to review your treatment.

Regular checks of blood pressure are recommended in the first 3-4 days after starting treatment.

Long term use

In case you are treated with Cabergoline1A Farma for a long period, your physician will check before starting treatment whether your heart, lungs and kidneys are in good condition. He/she will also have an echocardiogram (an ultrasound test of the heart) taken before treatment is started and at regular intervals during treatment. If fibrotic reactions occur treatment will have to be discontinued.

Other medicines and Cabergoline1A Farma

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Some medicines, if taken at the same time as Cabergoline1A Farma, can interfere with the effects of your tablets. These are medicines for:

medicines to prevent vomiting (e.g. metoclopramide)

antibiotics (e.g. erythromycin)

Cabergoline1A Farma with food and drink

TakeCabergoline1A Farma preferably with meals to reduce side effects.

Pregnancy, breast-feeding and fertility


There is only limited experience of the use of Cabergoline1A Farma during pregnancy. You should therefore consult your doctor if you are pregnant or plan to become pregnant before the treatment is started. If you are being treated with Cabergoline1A Farmaand become pregnant during this time you should contact your doctor as soon as possible; he will discuss the options with you. Contraception should be continued for at least 4 weeks after stopping Cabergoline-1A Farma.


Infertility can be reversed in women taking Cabergoline-1A Farma, and pregnancy can occur before the menstrual cycle has normalised. Use contraception during treatment if necessary, and continue for at least 4 weeks after stopping Cabergoline-1A Farma.


It is not known whether cabergoline passes into breast milk. As Cabergoline1A Farmawill stop you from producing milk for your baby, you should not take Cabergoline1A Farmaif you plan to breastfeed. If you need to take Cabergoline1A Farma you should use another method for feeding your baby.

Driving and using machines

Cabergoline1A Farma can reduce your ability to react quickly as it reduces blood pressure. This should be considered in cases where a high level of alertness is required, e.g. driving a car or in precision work.

Cabergoline1A Farma can cause extreme drowsiness and sudden sleep episodes can occur. If you are affected by these you should not drive or operate machinery. If affected, consult your doctor.

Cabergoline1A Farma contains lactose.

If you have been told by your doctor that you have an intolerance to some sugars contact your doctor before taking this medicine.

3. How to take Cabergoline1A Farma

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Open the closure, push and break through the liner to access the contents.

Take the tablets with meals to reduce certain side effects such as nausea, vomiting and stomach pains.

Adults and elderly patients:

The dose is determined by your doctor who adjusts it to suit your needs. The usual dose at the start of treatment is 0.5 -1 mg cabergoline daily. The dose is then increased gradually as directed by the doctor up to a suitable maintenance dose.

The usual maintenance dose is from 2 mg to a maximum of 3 mg cabergoline daily.

Cabergoline1A Farma 1mg and 2mg tablets can be broken into two equal halves.

Patients with hepatic or renal dysfunction

These tablets should be used with caution.

Children and adolescents

Cabergoline1A Farma is not recommended in patients under 16 years of age.

If you take more Cabergoline1A Farmathan you should

It is important not to take too many tablets. Contact your nearest hospital Accident and Emergency department or a doctor for advice, if you have taken too many tablets or if you think a child has swallowed any. Take this leaflet and any remaining tablets with you.

Symptoms of overdose may include nausea, vomiting, reduced blood pressure, drop in blood pressure following a change of body position into a more upright position, stomach pain, changes in behaviour, confusion or hallucinations (seeing things).

If you forget to take Cabergoline1A Farma

If you forget to take a dose at the right time, you can take it as soon as you remember.

If it is almost time to take the next dose, skip the forgotten dose and take the next dose as usual. Do not take a double dose to make up for a forgotten dose.

If you stop taking Cabergoline1A Farma

If you stop taking Cabergoline1A Farmathe symptoms of your illness may become more severe and you should consult your doctor before you discontinue therapy. Cabergoline takes many days to be cleared from the bloodstream and effects may worsen over a 2 week period resulting in worsening of symptoms of Parkinson's disease.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor immediately if you experience any of the following symptoms. These

symptoms can be severe:

heart valve and related disorders e. g. inflammation (pericarditis) or leaking of fluid in the pericardium (pericardial effusion). The early symptoms may be one or more of the following: difficulty breathing, shortness of breath, chest or back pain and swollen legs. This is a very common side effect (may affect more than 1 in 10 people).

Development of a widespread itchy rash, difficulty breathing with or without wheezing, feeling faint, unexplained swelling of the body or tongue or any other symptoms which appear to come on rapidly after taking this medication and make you feel unwell. These may be indicative of a hypersensitivity reaction. This is an uncommon side effect (may affect up to 1 in 100 people).

You may experience the following side effects:

Very common: may affect more than 1 in 10 people

Nausea, swelling of tissues in the lower limbs due to the accumulation of fluids (peripheral edema),

Common: may affect up to 1 in 10 people

Vomiting, digestive disturbances, constipation, inflammation of the stomach lining (gastritis), chest pain (angina), hallucinations, confusion, sleep disturbances, somnolence, dizziness, headache, increased libido, shortness of breath, weakness/lack of energy and motivation, involuntary movements (dyskinesias), drop in blood pressure following a change of body position into a more upright position, low blood pressure after treatment for a long time, decrease in the value of specific blood components (haemoglobin, hematocrit, and/or red blood cell), abnormal liver function tests.

Uncommon: may affect up to 1 in 100 people

Redness, swelling and pain in the extremities of the arms and legs (erythromelalgia), excessive movements (hyperkinesia), fluid in the layers of the membrane lining the lungs and chest cavity, formation of scar tissue in the lung (pulmonary fibrosis), rash, fatigue, delusions, psychotic disorder, abnormal hepatic function, swelling of tissues due to the accumulation of fluids (edema).

Very rare: may affect up to 1 in 10,000 people

Formation of scar tissue in the lung (fibrosis).

Not known: frequency cannot be estimated from the available data

Aggression, sudden sleep onset, fainting, hair loss, leg cramps, disorder of blood vessels (digital vasospasm), problems with the respiratory system, increased blood values of a specific enzyme called creatinine phosphokinase, , tremor, problems with your eyesight, inflammation of the lining of the lung (pleuritis), chest pain.

Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:

Tell your doctor if you experience any of these behaviors; they will discuss ways of managing or reducing the symptoms.

Reporting of side effects

If you get side effects , talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effect directly via [TO BE COMPLETED NATIONALLY]. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Cabergoline1A Farma

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and bottle after EXP. The expiry date refers to the last day of that month. The shelf life after the first opening is 3 months.

Keep the bottle tightly closed in order to protect from light and moisture.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Cabergoline1A Farma contains

The active substance is cabergoline.

Each tablet contains either 1 mg or 2 mg cabergoline.

The other ingredients are anhydrous lactose (see end of Section 2 for further information on lactose) and L-Leucine

What Cabergoline1A Farma looks like and contents of the pack

Cabergoline1A Farma, 1 mg, tablets: White, oval, uncoated, tablet, scored and debossed with “C 1“ on one side.

Cabergoline1A Farma, 2 mg, tablets: White, oval, uncoated, biconvex tablet, scored and debossed with “C 2“ on one side.

The tablet can be divided into equal halves by a breakline.

Amber glass bottle with PP cap: 2, 4, 8,10, 16, 20, 30, 40, 48, 60, 90, 96 and 100 tablets.

The bottle contains a silicagel capsule.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

[To be completed nationally]

This medicinal product is authorised in the Member States of the EEA under the following names:

[To be completed nationally]

This leaflet was last approved in 2014-11-26

[To be completed nationally]